Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations

Evidence suggests increased risk of aminoglycoside-associated ototoxicity in patients with mitochondrial mutations, including cases with serum levels within recommended range. Genetic testing should not delay urgently needed treatment but may be considered in some situations.

Source:

Medicines and Healthcare products Regulatory Agency